Search

Your search keyword '"Bencardino, Katia"' showing total 208 results
Start Over Author "Bencardino, Katia"
208 results on '"Bencardino, Katia"'

3. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, Michele, Macchini, Marina, Orsi, Giulia, Peretti, Umberto, Valente, Mariamaddalena, Giommoni, Elisa, Antonuzzo, Lorenzo, Di Costanzo, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Lonardi, Sara, Buggin, Federica, Milella, Michele, Palmerio, Silvia, Cavanna, Luigi, Di Nunzio, Camilla, Di Marco, Maria Cristina, Grassi, Elisa, Spada, Massimiliano, Messina, Marco, Cordio, Stefano, Avola, Francesco, Aprile, Giuseppe, Pagano, Salvatore, Simionato, Francesca, Cardellino, Giovanni Gerardo, Majer, Federica, Maiello, Evaristo, Latiano, Tiziana Pia, Chiarazzo, Cinzia, Artioli, Fabrizio, Razzini, Giorgia, Pasqualini, Antonella, Ghidini, Michele, Binda, Elisa, Lazzarelli, Silvia, Bozzarelli, Silvia, Sala, Simona, Luppi, Gabriele, Pettorelli, Elisa, Spallanzani, Andrea, Vicario, Giovanni, Salmaso, Flavia, Basso, Marco, Silvestris, Nicola, Del Curatolo, Sabina, Zustovich, Fable, Bongiovanni, Francesca, Longobardi, Ciro, Sandi, Ilenia, Fontanella, Caterina, Montelatici, Silvia, Giordano, Monica, Luchena, Giovanna, Gilardoni, Micol, Tamburini, Emiliano, Rudnas, Britt, Venturini, Barbara, Merelli, Barbara, Negrini, Giorgia, Vici, Elio Maria, Marabese, Alessandra, Garetto, Cristina, Curcio, Paola, Cinieri, Saverio, Cinefra, Margherita, Ferrara, Pasqualinda, Cantore, Maurizio, Morselli, Patrizia, Fumi, Guglielmo, Isidori, Agnese, Ciccarese, Giovanni, Paolo Frassineti, Giovanni Luca, Pagan, Flavia, Vaccaro, Vanja, Spoto, Chiara, Ferrara, Marianna, Garufi, Carlo, Caporale, Marta, Vasile, Enrico, Salani, Francesca, Barone, Elisa, Berardi, Rossana, Onofri, Azzurra, Ballatore, Zelmira, Lucarelli, Alessandra, Barucca, Alessandra, Pancotti, Amedeo, Scipioni, Teresa, Bencardino, Katia, Marrapese, Giovanna, Idotta, Laura, Petrelli, Fausto, Lonati, Veronica, Ceribelli, Anna, Giuli, Angelo, Zannori, Cristina, Bassanelli, Maria, Mambrini, Andrea, Ginocchi, Laura, Orlandi, Massimo, Celio, Luigi, Niger, Monica, Biamonte, Lavinia, Tamberi, Stefano, Piancastelli, Alessandra, Papiani, Giorgio, Valli, Irene, Allione, Paolo, Boe, Maria Giovanna, Scartozzi, Mario, Lai, Eleonora, Pireddu, Annagrazia, Ziranu, Pina, Demurtas, Laura, Puzzoni, Marco, Mariani, Stefano, Pretta, Andrea, Liscia, Nicole, Savastano, Clementina, Malaspina, Valentina, Tonini, Giuseppe, Grassani, Teresa, Barco, Barbara, Pierosandro, Tagliaferri, Ciliberto, Domenico, Ierardi, Antonella, Calandruccio, Natale Daniele, Minotti, Vincenzo, Matocci, Roberta, Torri, Valter, Porcu, Luca, Rulli, Erica, De Simone, Irene, Carlucci, Luciano, Rulli, Eliana, Poli, Davide, Tonto, Paola, Scellato, Francesca, Pinto, Carmine, Reni, M., Giommoni, E., Bergamo, F., Milella, M., Cavanna, L., Di Marco, M.C., Spada, M., Cordio, S., Aprile, G., Cardellino, G.G., Maiello, E., Bernardini, I., Ghidini, M., Bozzarelli, S., Macchini, M., Orsi, G., De Simone, I., Rulli, Er., Porcu, L., Torri, V., and Pinto, C.

Published
2023
Full Text
View/download PDF

4. THU-486-YI A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events

Author

Tizzani, Marco, primary, Mazzarelli, Chiara, additional, Burlone, Michela Emma, additional, Carucci, Patrizia, additional, Caviglia, Gian Paolo, additional, Lisi, Chiara, additional, Canalis, Chiara, additional, Cesarini, Lucia, additional, Pirisi, Mario, additional, Acquaviva, Antonio, additional, Rolle, Emanuela, additional, Pochettino, Paolo, additional, Bencardino, Katia, additional, Villa, Federica, additional, Angiolillo, Martina, additional, Castellana, Eleonora, additional, Scaldaferri, Matilde, additional, Cattel, Francesco, additional, Airoldi, Mario, additional, Saracco, Giorgio Maria, additional, and Gaia, Silvia, additional

Published
2024
Full Text
View/download PDF

5. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer

Author

Tosi, Federica, Sartore-Bianchi, Andrea, Lonardi, Sara, Amatu, Alessio, Leone, Francesco, Ghezzi, Silvia, Martino, Cosimo, Bencardino, Katia, Bonazzina, Erica, Bergamo, Francesca, Fenocchio, Elisabetta, Martinelli, Erika, Troiani, Teresa, Siravegna, Giulia, Mauri, Gianluca, Torri, Valter, Marrapese, Giovanna, Valtorta, Emanuele, Cassingena, Andrea, Cappello, Giovanni, Bonoldi, Emanuela, Vanzulli, Angelo, Regge, Daniele, Ciardiello, Fortunato, Zagonel, Vittorina, Bardelli, Alberto, Trusolino, Livio, Marsoni, Silvia, and Siena, Salvatore

Published
2020
Full Text
View/download PDF

8. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Author

Sartore-Bianchi, Andrea, Lonardi, Sara, Martino, Cosimo, Fenocchio, Elisabetta, Tosi, Federica, Ghezzi, Silvia, Leone, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Ciardiello, Fortunato, Ardizzoni, Andrea, Amatu, Alessio, Bencardino, Katia, Valtorta, Emanuele, Grassi, Elena, Torri, Valter, Bonoldi, Emanuela, Sapino, Anna, Vanzulli, Angelo, Regge, Daniele, Cappello, Giovanni, Bardelli, Alberto, Trusolino, Livio, Marsoni, Silvia, and Siena, Salvatore

Published
2020
Full Text
View/download PDF

10. Liquid biopsy for rectal cancer: A systematic review

Author

Massihnia, Daniela, Pizzutilo, Elio Gregory, Amatu, Alessio, Tosi, Federica, Ghezzi, Silvia, Bencardino, Katia, Di Masi, Pietro, Righetti, Elena, Patelli, Giorgio, Scaglione, Francesco, Vanzulli, Angelo, Siena, Salvatore, and Sartore-Bianchi, Andrea

Published
2019
Full Text
View/download PDF

11. Clinicopathological characterisation ofMTAPalterations in gastrointestinal cancers

Author

Mauri, Gianluca, primary, Patelli, Giorgio, additional, Roazzi, Laura, additional, Valtorta, Emanuele, additional, Amatu, Alessio, additional, Marrapese, Giovanna, additional, Bonazzina, Erica, additional, Tosi, Federica, additional, Bencardino, Katia, additional, Ciarlo, Gabriele, additional, Mariella, Elisa, additional, Marsoni, Silvia, additional, Bardelli, Alberto, additional, Bonoldi, Emanuela, additional, Sartore-Bianchi, Andrea, additional, and Siena, Salvatore, additional

Published
2024
Full Text
View/download PDF

14. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

Author

Di Bartolomeo, Maria, Niger, Monica, Tirino, Giuseppe, Petrillo, Angelica, Berenato, Rosa, Laterza, Maria Maddalena, Pietrantonio, Filippo, Morano, Federica, Antista, Maria, Lonardi, Sara, Fornaro, Lorenzo, Tamberi, Stefano, Giommoni, Elisa, Zaniboni, Alberto, Rimassa, Lorenza, Tomasello, Gianluca, Sava, Teodoro, Spada, Massimiliano, Latiano, Tiziana, Bittoni, Alessandro, Bertolini, Alessandro, Proserpio, Ilaria, Bencardino, Katia Bruna, Graziano, Francesco, Beretta, Giordano, Galdy, Salvatore, Ventriglia, Jole, Scagnoli, Simone, Spallanzani, Andrea, Longarini, Raffaella, and De Vita, Ferdinando

Published
2018
Full Text
View/download PDF

15. Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).

Author

Siena, Salvatore, primary, Amatu, Alessio, additional, Bencardino, Katia, additional, Zampino, M. Giulia, additional, Bergamo, Francesca, additional, Mosconi, Stefania, additional, Bracco, Francesco, additional, Gerardi, Marianna Alessandra, additional, Galuppo, Sara, additional, Carnevali, Pietro, additional, Petz, Wanda, additional, Pilati, Pierluigi, additional, Tosi, Federica, additional, Mariano, Sara, additional, Bonazzina, Erica, additional, Forti, Edoardo, additional, Ghezzi, Silvia, additional, Pucciarelli, Salvatore, additional, Torri, Valter, additional, and Sartore-Bianchi, Andrea, additional

Published
2023
Full Text
View/download PDF

17. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Author

Sartore-Bianchi, Andrea, Trusolino, Livio, Martino, Cosimo, Bencardino, Katia, Lonardi, Sara, Bergamo, Francesca, Zagonel, Vittorina, Leone, Francesco, Depetris, Ilaria, Martinelli, Erika, Troiani, Teresa, Ciardiello, Fortunato, Racca, Patrizia, Bertotti, Andrea, Siravegna, Giulia, Torri, Valter, Amatu, Alessio, Ghezzi, Silvia, Marrapese, Giovanna, Palmeri, Laura, Valtorta, Emanuele, Cassingena, Andrea, Lauricella, Calogero, Vanzulli, Angelo, Regge, Daniele, Veronese, Silvio, Comoglio, Paolo M, Bardelli, Alberto, Marsoni, Silvia, and Siena, Salvatore

Published
2016
Full Text
View/download PDF

18. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)

Author

Ricotta, Riccardo, Verrioli, Antonella, Ghezzi, Silvia, Porcu, Luca, Grothey, A., Falcone, Alfredo, Van Cutsem, Eric, Argilés, Guillem, Adenis, Antoine, Ychou, Marc, Barone, Carlo, Bouché, Olivier, Peeters, Marc, Humblet, Yves, Mineur, Laurent, Sobrero, Alberto F., Hubbard, Joleen M., Cremolini, Chiara, Prenen, Hans, Tabernero, Josep, Jarraya, Hajer, Mazard, Thibault, Deguelte-Lardiere, Sophie, Papadimitriou, Konstantinos, Van den Eynde, Marc, Pastorino, Alessandro, Redaelli, Daniela, Bencardino, Katia, Funaioli, Chiara, Amatu, Alessio, Carlo-Stella, Giulia, Torri, Valter, Sartore-Bianchi, Andrea, Vanzulli, Angelo, and Siena, Salvatore

Published
2016
Full Text
View/download PDF

19. Esophageal Cancer with Early Onset in a Patient with Cri du Chat Syndrome.

Author

Danesino, Cesare, Gualtierotti, Monica, Origi, Matteo, Cistaro, Angelina, Malacarne, Michela, Massidda, Matteo, Bencardino, Katia, Coviello, Domenico, Albani, Giovanni, Schiera, Irene Giovanna, Liava, Alexandra, and Guala, Andrea

Subjects
ESOPHAGEAL cancer, PAIN threshold, GASTROESOPHAGEAL reflux, SYNDROMES, DISEASE risk factors, INSULAR cortex
Abstract

Background: In Cri du Chat (CdC), cancer as comorbidity is extremely rare. In databases from Denmark, Spain, Australia, New Zealand, and Japan, no cancer was reported; in Italy and Germany, four cancers were identified out of 321 CdCs. Methods: In a 29-year-old CdC patient, clinical investigations following hematemesis led to the diagnosis of esophageal adenocarcinoma (EAC). A high pain threshold was also observed. Conventional and molecular cytogenetic defined the size of the deletion, and exome analysis on the trio completed the molecular work. Results: Cytogenetic analysis showed a de novo chromosomal alteration: 46,XY,ishdel(5)(p14.3)(D5S28-) and arr[GRCh37] 5p15.33p14.3(1498180_19955760)x1. A quantitative sensory test demonstrated a high heat threshold. A 18f-fluorodeoxyglucose PET/TC scan of the brain failed to detect reduction of metabolism in the somatosensory area or insular cortex. Exome analysis in the trio (patient and parents) failed to identify variants to be interpreted as a likely risk factor for EAC. Conclusion: We conclude that the presence of well-known risk factors (maleness, obesity, gastroesophageal reflux, and Barrett's metaplasia) in a patient with very limited capability of expressing discomfort or referring clinical symptoms have been the main risk factors for developing EAC. At present, based on the available data, there is no evidence of any increased risk of developing cancer in CdC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Data from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure Legends from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figures 1 - 2 from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables 1-6 from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 1 from Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Author

Amatu, Alessio, primary, Sartore-Bianchi, Andrea, primary, Moutinho, Catia, primary, Belotti, Alessandro, primary, Bencardino, Katia, primary, Chirico, Giuseppe, primary, Cassingena, Andrea, primary, Rusconi, Francesca, primary, Esposito, Anna, primary, Nichelatti, Michele, primary, Esteller, Manel, primary, and Siena, Salvatore, primary

Published
2023
Full Text
View/download PDF

25. Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Author

Mauri, Gianluca, primary, Patelli, Giorgio, additional, Gori, Viviana, additional, Lauricella, Calogero, additional, Mussolin, Benedetta, additional, Amatu, Alessio, additional, Bencardino, Katia, additional, Tosi, Federica, additional, Bonazzina, Erica, additional, Bonoldi, Emanuela, additional, Bardelli, Alberto, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2023
Full Text
View/download PDF

26. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Author

Valtorta, Emanuele, Martino, Cosimo, Sartore-Bianchi, Andrea, Penaullt-Llorca, Frédérique, Viale, Giuseppe, Risio, Mauro, Rugge, Massimo, Grigioni, Walter, Bencardino, Katia, Lonardi, Sara, Zagonel, Vittorina, Leone, Francesco, Noe, Johannes, Ciardiello, Fortunato, Pinto, Carmine, Labianca, Roberto, Mosconi, Stefania, Graiff, Claudio, Aprile, Giuseppe, Frau, Barbara, Garufi, Carlo, Loupakis, Fotios, Racca, Patrizia, Tonini, Giuseppe, Lauricella, Calogero, Veronese, Silvio, Truini, Mauro, Siena, Salvatore, Marsoni, Silvia, and Gambacorta, Marcello

Published
2015
Full Text
View/download PDF

28. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience

Author

Sartore-Bianchi, Andrea, Amatu, Alessio, Bonazzina, Erica, Stabile, Stefano, Giannetta, Laura, Cerea, Giulio, Schiavetto, Ilaria, Bencardino, Katia, Funaioli, Chiara, Ricotta, Riccardo, Cipani, Tiziana, Schirru, Michele, Gambi, Valentina, Palmeri, Laura, Carlo-Stella, Giulia, Rusconi, Francesca, Di Bella, Sara, Burrafato, Giovanni, Cassingena, Andrea, Valtorta, Emanuele, Lauricella, Calogero, Pazzi, Federica, Gambaro, Alessandra, Ghezzi, Silvia, Marrapese, Giovanna, Tarenzi, Emiliana, Veronese, Silvio, Truini, Mauro, Vanzulli, Angelo, and Siena, Salvatore

Published
2017
Full Text
View/download PDF

30. Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Author

Mauri, Gianluca, primary, Patelli, Giorgio, additional, Gori, Viviana, additional, Lauricella, Calogero, additional, Mussolin, Benedetta, additional, Amatu, Alessio, additional, Bencardino, Katia, additional, Tosi, Federica, additional, Bonazzina, Erica, additional, Bonoldi, Emanuela, additional, Bardelli, Alberto, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2022
Full Text
View/download PDF

31. Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study

Author

Amatu, Alessio, primary, Mauri, Gianluca, additional, Tosi, Federica, additional, Bencardino, Katia, additional, Bonazzina, Erica, additional, Gori, Viviana, additional, Ruggieri, Lorenzo, additional, Arena, Sabrina, additional, Bardelli, Alberto, additional, Marsoni, Silvia, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2022
Full Text
View/download PDF

32. Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study.

Author

Mauri, Gianluca, primary, Amatu, Alessio, additional, Tosi, Federica, additional, Bencardino, Katia, additional, Bonazzina, Erica, additional, Gori, Viviana, additional, Ruggieri, Lorenzo, additional, Arena, Sabrina, additional, Bardelli, Alberto, additional, Marsoni, Silvia, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2022
Full Text
View/download PDF

34. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Author

Misale, Sandra, Yaeger, Rona, Hobor, Sebastijan, Scala, Elisa, Janakiraman, Manickam, Liska, David, Valtorta, Emanuele, Schiavo, Roberta, Buscarino, Michela, Siravegna, Giulia, Bencardino, Katia, Cercek, Andrea, Chen, Chin-Tung, Veronese, Silvio, Zanon, Carlo, Sartore-Bianchi, Andrea, Gambacorta, Marcello, Gallicchio, Margherita, Vakiani, Efsevia, Boscaro, Valentina, Medico, Enzo, Weiser, Martin, Siena, Salvatore, Nicolantonio, Federica Di, Solit, David, and Bardelli, Alberto

Subjects
Drug therapy, Physiological aspects, Genetic aspects, Dosage and administration, Health aspects, Cetuximab -- Dosage and administration -- Physiological aspects, Epidermal growth factor receptors -- Health aspects, Gene mutation -- Health aspects, Drug resistance -- Physiological aspects, Colorectal cancer -- Development and progression -- Genetic aspects -- Health aspects -- Analysis -- Drug therapy, GTPases -- Genetic aspects -- Health aspects, Gene mutations -- Health aspects, Guanosine triphosphatase -- Genetic aspects -- Health aspects
Abstract

Defining the molecular bases of secondary resistance to anti-EGFR therapies is crucial to monitor, prevent and/or overcome drug refractoriness. To identify potential mechanisms of cetuximab resistance, we generated cetuximab-resistant variants [...], A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers (1). After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug (2). The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood (3-8). Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases. KRAS mutant alleles were detectable in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.

Published
2012
Full Text
View/download PDF

38. Young-onset colorectal cancer: treatment-related nausea, vomiting and diarrhoea

Author

Mauri, Gianluca, Pedrani, Martino, Ghezzi, Silvia, Bencardino, Katia, Mariano, Sara, Bonazzina, Erica, Serra, Francesco, Pedrazzoli, Paolo, Caccialanza, Riccardo, Cavestro, Giulia Martina, Siena, Salvatore, Artale, Salvatore, and Sartore-Bianchi, Andrea

Abstract

ObjectivesEarly-onset colorectal cancer (EO-CRC) incidence is increasing, raising a clinical challenge. Clinicians tend to treat EO-CRC patients with more intensive regimens despite the lack of survival benefits, based on an age-related bias. Limited evidence is available regarding treatment-related toxicities in this peculiar subset of patients.MethodsWe performed a literature search in MEDLINE/PubMed, EMBASE and Scopus, looking for reporting of nausea, vomiting and diarrhoea occurring in patients with EO-CRC, defined by age lower than 50 years old at initial diagnosis, while receiving anticancer treatment.Results2318 records were screened and 9 full-text articles were considered eligible for inclusion for a total of 59 783 patients (of whom 8681 EO-CRC patients). We found nausea and vomiting occurring at higher incidence among EO-CRC compared with older patients, while no difference was reported as for diarrhoea. Peritoneal involvement, age younger than 40, female gender, suboptimal adherence to guidelines and oxaliplatin might represent potential risk factors for increased nausea and vomiting in patients with EO-CRC.ConclusionEO-CRC patients experience more nausea and vomiting but equal or less diarrhoea compared with older patients. Adherence to clinical guidelines is recommended, and more data are warranted to assess if an enhanced antiemetic approach might be required, particularly in case of specific risk factors.

Published
2023
Full Text
View/download PDF

39. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer

Author

Mauri, Gianluca, primary, Bonazzina, Erica, additional, Amatu, Alessio, additional, Tosi, Federica, additional, Bencardino, Katia, additional, Gori, Viviana, additional, Massihnia, Daniela, additional, Cipani, Tiziana, additional, Spina, Francesco, additional, Ghezzi, Silvia, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2021
Full Text
View/download PDF

43. High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib

Author

Amatu, Alessio, primary, Schirripa, Marta, additional, Tosi, Federica, additional, Lonardi, Sara, additional, Bencardino, Katia, additional, Bonazzina, Erica, additional, Palmeri, Laura, additional, Patanè, Damiano Alfio, additional, Pizzutilo, Elio Gregory, additional, Mussolin, Benedetta, additional, Bergamo, Francesca, additional, Alberti, Giulia, additional, Intini, Rossana, additional, Procaccio, Letizia, additional, Arese, Marco, additional, Marsoni, Silvia, additional, Nichelatti, Michele, additional, Zagonel, Vittorina, additional, Siena, Salvatore, additional, Bardelli, Alberto, additional, Loupakis, Fotios, additional, Di Nicolantonio, Federica, additional, Sartore-Bianchi, Andrea, additional, and Barault, Ludovic, additional

Published
2019
Full Text
View/download PDF

44. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Author

Manzoni Mariangela, Ricci Vincenzo, Bencardino Katia, Santini Daniele, Vincenzi Bruno, Canestrari Emanuele, Galluccio Nadia, Catalano Vincenzo, Frumento Paolo, Schirripa Marta, Masi Gianluca, Cremolini Chiara, Ruzzo Annamaria, Salvatore Lisa, Loupakis Fotios, Danova Marco, Tonini Giuseppe, Magnani Mauro, Falcone Alfredo, and Graziano Francesco

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of bevacizumab. Methods Genomic DNA of 111 consecutive metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab was obtained from blood samples. VEGF -2578 C/A, -1498 C/T, + 405 C/G, + 936 C/T polymorphisms were analyzed by means of PCR-RFLP. DNA samples from 107 patients treated with FOLFIRI alone served as historical control group. The relation of VEGF polymorphisms with PFS, evaluated through Kaplan-Meier method and log-rank test, was the primary end-point. An interaction test with a Cox model has been performed in order to demonstrate the heterogeneity of the effect of VEGF -1498 C/T polymorphism between bevacizumab-and control group. Results In the bevacizumab-group median PFS and OS of patients carrying VEGF -1498 C/C, C/T and T/T allelic variants were, respectively, 12.8, 10.5, 7.5 months (p = 0.0046, log-rank test) and 27.3, 20.5, 18.6 months (p = 0.038, log-rank test). VEGF -1498 T/T genotype was associated with shorter PFS (HR = 2.13, [1.41-5.10], p = 0.0027). In the control group no significant association of VEGF -1498 C/T allelic variants and PFS or OS was found. Interaction between VEGF -1498 C/T variants and treatment effect suggested that the relation of VEGF -1498 T/T genotype with shorter PFS was caused by the effect of bevacizumab (p = 0.011). Other investigated polymorphisms did not affect the outcome. Conclusions These data suggest a possible role for VEGF -1498 C/T variants in predicting the efficacy of bevacizumab in the up-front treatment of metastatic colorectal cancer patients. A molecular tool for selecting subjects candidate to benefit from the anti-VEGF could be important for clinical practice. The retrospective and exploratory design of the present study, coupled with the non-randomized nature of the comparison between treated and untreated patients, imply that these results should be considered as hypothesis generators. A prospective validating trial is currently ongoing.

Published
2011
Full Text
View/download PDF

45. Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

Author

Sartore-Bianchi, Andrea, Bencardino, Katia, Di Nicolantonio, Federica, Pozzi, Federico, Funaioli, Chiara, Gambi, Valentina, Arena, Sabrina, Martini, Miriam, Lamba, Simona, Cassingena, Andrea, Schiavo, Roberta, Bardelli, Alberto, and Siena, Salvatore

Published
2012
Full Text
View/download PDF

46. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

Author

Barault, Ludovic, primary, Amatu, Alessio, additional, Siravegna, Giulia, additional, Ponzetti, Agostino, additional, Moran, Sebastian, additional, Cassingena, Andrea, additional, Mussolin, Benedetta, additional, Falcomatà, Chiara, additional, Binder, Alexandra M, additional, Cristiano, Carmen, additional, Oddo, Daniele, additional, Guarrera, Simonetta, additional, Cancelliere, Carlotta, additional, Bustreo, Sara, additional, Bencardino, Katia, additional, Maden, Sean, additional, Vanzati, Alice, additional, Zavattari, Patrizia, additional, Matullo, Giuseppe, additional, Truini, Mauro, additional, Grady, William M, additional, Racca, Patrizia, additional, Michels, Karin B, additional, Siena, Salvatore, additional, Esteller, Manel, additional, Bardelli, Alberto, additional, Sartore-Bianchi, Andrea, additional, and Di Nicolantonio, Federica, additional

Published
2017
Full Text
View/download PDF

47. Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer

Author

Siena, Salvatore, primary, Sartore-Bianchi, Andrea, additional, Trusolino, Livio, additional, Martino, Cosimo, additional, Bencardino, Katia, additional, Lonardi, Sara, additional, Zagonel, Vittorina, additional, Leone, Francesco, additional, Martinelli, Erika, additional, Ciardiello, Fortunato, additional, Racca, Patrizia, additional, Amatu, Alessio, additional, Palmeri, Laura, additional, Valtorta, Emanuele, additional, Ghezzi, Silvia, additional, Vanzulli, Angelo, additional, Regge, Daniele, additional, Veronese, Silvio, additional, Bardelli, Alberto, additional, and Marsoni, Silvia, additional

Published
2017
Full Text
View/download PDF

48. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, additional, Ou, Sai-Hong Ignatius, additional, Patel, Manish, additional, Ahn, Myung Ju, additional, Lee, Jeeyun, additional, Bauer, Todd M., additional, Farago, Anna F., additional, Wheler, Jennifer J., additional, Liu, Stephen V., additional, Doebele, Robert, additional, Giannetta, Laura, additional, Cerea, Giulio, additional, Marrapese, Giovanna, additional, Schirru, Michele, additional, Amatu, Alessio, additional, Bencardino, Katia, additional, Palmeri, Laura, additional, Sartore-Bianchi, Andrea, additional, Vanzulli, Angelo, additional, Cresta, Sara, additional, Damian, Silvia, additional, Duca, Matteo, additional, Ardini, Elena, additional, Li, Gang, additional, Christiansen, Jason, additional, Kowalski, Karey, additional, Johnson, Ann D., additional, Patel, Rupal, additional, Luo, David, additional, Chow-Maneval, Edna, additional, Hornby, Zachary, additional, Multani, Pratik S., additional, Shaw, Alice T., additional, and De Braud, Filippo G., additional

Published
2017
Full Text
View/download PDF

49. Analysis of early distant metastases of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.

Author

Lonardi, Sara, primary, Cionini, Luca, additional, Di Fabio, Francesca, additional, Pinto, Carmine, additional, Cordio, Stefano Sergio, additional, Rosati, Gerardo, additional, Bencardino, Katia, additional, Tagliagambe, Angiolo, additional, Frisinghelli, Michela, additional, Bergamo, Francesca, additional, Rosetti, Paola, additional, Bonetti, Andrea, additional, Negru, Maria Emanuela, additional, Tronconi, Maria Chiara, additional, Luppi, Gabriele, additional, Chiaulon, Germana, additional, Granetto, Cristina, additional, Niespolo, Rita, additional, Boni, Luca, additional, and Aschele, Carlo, additional

Published
2016
Full Text
View/download PDF

50. Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

Author

Venturini, Filippo, primary, Gambi, Valentina, additional, Di Lernia, Stefano, additional, Vanzulli, Angelo, additional, Bramerio, Manuela, additional, Bencardino, Katia, additional, Amatu, Alessio, additional, Cipani, Tiziana, additional, Forti, Edoardo, additional, Tarenzi, Emiliana, additional, Sartore-Bianchi, Andrea, additional, Pugliese, Raffaele, additional, and Siena, Salvatore, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results